Photo: Times UK
Adar Poonawalla Says Vaccine Shortage To Continue For Few Months
Serum Institute of India CEO Adar Poonawalla has stated that the vaccine shortage is likely to continue for the next few months. Currently, the company is producing 60-70 million doses of Covishield a month but eyeing to ramp up the capacity to 100 million doses per month by July. He stated that the production capacity was not upped earlier as authorities did not expect the second COVID-19 wave.
Tags: Adar Poonawalla, SII, COVID-19 VACCINE HOARD, Vaccine Shortage
Courtesy: Times now news
Photo: The Indian Express
Vaccine Maker SII's CEO Adar Poonawalla Given Y-Security Amid Threats
Vaccine-maker Serum Institute of India (SII)'s CEO Adar Poonawalla has been granted Y-category security by the Home Ministry. Based on the threat perception report and to be handled by the CRPF, the security cover will include 11 personnel comprising CRPF commandos and policemen. SII is responsible for manufacturing 'Covishield' vaccine, whose rate was recently cut for states, from Rs 400 to Rs 300, after Poonawalla announced it on April 28… read-more
Tags: SII, Adar Poonawalla, Covishield vaccine, Y-Category security
Courtesy: The Times of India
Photo: News 18
Bharat Biotech To Sell Covaxin At Rs 600 For States, Rs 1,200 For Pvt Hospitals
Bharat Biotech on April 24 announced to sell its COVID-19 vaccine Covaxin at Rs 1,200 for private hospitals and Rs 600 for state governments. The firm said that Covaxin is a "highly purified vaccine" and is expensive to manufacture. Meanwhile, the other vaccine maker, Serum Institute of India, would be selling its vaccine 'Covishield' at a price of Rs 400 for states and at Rs 600 for private hospitals.… read-more
Tags: Bharat biotech, Covaxin, Covid Vaccine, SII
Courtesy: NDTV
Photo: The Economic Times
SII To Sell Covishield At Rs 600 To Pvt Hospitals, Rs 400 To States
The Serum Institute of India on April 21 announced to sell its Covishield vaccine to state governments at Rs 400 and to the private hospitals at Rs 600/dose. SII said that 50% of its forthcoming vaccine production will be dedicated to Centre’s vaccination program and other 50% for states and private hospitals. Welcoming the Centre’s liberalised vaccination policy, SII assured that vaccines will be available in 4-5 months.
Tags: SII, COVISHIELD, Central Government, Covid-19 Vaccine, Private Hospitals
Courtesy: Live Mint
Photo: Business Standard
AstraZeneca Sends Legal Notice To SII Over Delays In Vaccine Supply
British-Swedish pharmaceutical company AstraZeneca has served a legal notice to the Serum Institute of India over delays in the supply of COVID-19 vaccine Covishield. SII CEO Adar Poonawalla said, “Serum Institute is not able to fulfil (contractual obligations) due to its prioritisation of Indian supplies." Moreover, denying to comment on the notice and terming it "confidential", Poonawalla said the company is trying to resolve and manage the… read-more
Tags: COVISHIELD, Adar Poonawalla, SII, AstraZeneca
Courtesy: NDTV
Photo: The Economic Times
Serum Institue Plans To Launch Covovax By August: Adar Poonawalla
The Serum Institute of India is planning to launch another COVID-19 vaccine 'Covovax' by August 2021. Developed by Novavax, an American vaccine maker, the Covovax will be stockpiled by the SII, for its testing on the Indian population, starting from April. Speaking at the Bloomberg Equity Index, SII CEO Adar Poonawalla said Covovax distribution will start after receiving the government’s nod. Poonawalla added that the global COVAX facility is… read-more
Tags: Novavax, Adar Poonawalla, SII, Covid-19 Vaccine, COVAX, WHO
Courtesy: The Indian Express
Photo: Quartz
SII Awaits Govt Approval To Conduct Trials Of Novavax COVID Vaccine
The Serum Institute of India has applied to the Drugs Controller General of India seeking permission to conduct domestic trials of ‘Novavax’ coronavirus vaccine. Reportedly, the US-based company claimed that Novavax showed 89.3% and 60% effectiveness during the trials in the UK and Africa respectively. Earlier, Novavax and SII collaborated to produce 2 billion vaccine doses. Besides, Novavax has received around $388 million from the Coalition… read-more
Tags: Novavax, SII, Serum Institute of India, DCGI
Courtesy: Live Mint
Photo: The Indian Express
Pune SII Fire: CEO Adar Poonawalla Estimates Rs 1,000 Cr Loss
A day after the fire outbreak at its Pune-based plant, the Serum Institute of India CEO Adar Poonawalla has admitted a financial loss of Rs 1,000 crore. Adar said, "The fire has damaged machinery installed for rotavirus and BCG vaccine production." However, has assured that the production facility of COVID-19 vaccine - Covishield - has not been affected. Moreover, three to four floors of the SII facility were damaged.
Tags: Fire at SII, SII, Adar Poonawalla, Covishield vaccine
Courtesy: Deccan Herald
Photo: DNA India
SII Announces Compensation Of Rs 25 Lakh To Families Of Deceased
Pune-based the Serum Institute of India has announced a Rs 25-lakh compensation to the families of five deceased who lost their lives in the fire outbreak on January 21. Expressing his grief, SII CEO Adar Poonawalla said, "Extremely sorrowful day for all of us". Reportedly, four other people were evacuated from the SII's Manjari premises . Meanwhile, the SII and Maharashtra CM Uddav Thackary have assured that the accident will not affect… read-more
Tags: Serum Institute of India, SII, Fire at SII, Fire Outbreak, Pune
Courtesy: Times Now
Photo: BBC
Koderma CMO Orders To Withhold Salaries Of Staff Avoiding Vaccination
Displaying a strict stance on COVID vaccination drive, Jharkhand's Koderma Chief Medical Officer and District Vaccination Officer have mandated vaccination for their staff. Besides, contradicting the fact of inoculation being voluntary, the officers have warned of salary interruption of staff until they get vaccinated. Moreover, the administration said that the transactions will resume only after displaying proof of the vaccination shot.… read-more
Tags: Jharkhand, Koderma, Covid-19 Vaccine, SII
Courtesy: The Tribune
